These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21212673)

  • 21. Cardiac pacemaker I(f) current and its inhibition by heart rate-reducing agents.
    DiFrancesco D
    Curr Med Res Opin; 2005 Jul; 21(7):1115-22. PubMed ID: 16004681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice.
    Custodis F; Baumhäkel M; Schlimmer N; List F; Gensch C; Böhm M; Laufs U
    Circulation; 2008 May; 117(18):2377-87. PubMed ID: 18443241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cardiac pacemaker current.
    Baruscotti M; Barbuti A; Bucchi A
    J Mol Cell Cardiol; 2010 Jan; 48(1):55-64. PubMed ID: 19591835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N
    Therapie; 2009; 64(2):111-4. PubMed ID: 19664404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N; Bhargava B
    Am J Cardiovasc Drugs; 2011; 11(1):1-12. PubMed ID: 21090826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity.
    Thollon C; Bedut S; Villeneuve N; Cogé F; Piffard L; Guillaumin JP; Brunel-Jacquemin C; Chomarat P; Boutin JA; Peglion JL; Vilaine JP
    Br J Pharmacol; 2007 Jan; 150(1):37-46. PubMed ID: 17128289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression.
    Suffredini S; Stillitano F; Comini L; Bouly M; Brogioni S; Ceconi C; Ferrari R; Mugelli A; Cerbai E
    Br J Pharmacol; 2012 Mar; 165(5):1457-66. PubMed ID: 21838751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs.
    Colin P; Ghaleh B; Monnet X; Hittinger L; Berdeaux A
    J Pharmacol Exp Ther; 2004 Jan; 308(1):236-40. PubMed ID: 14569053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. I(f) channel inhibitor ivabradine lowers heart rate in mice with enhanced sympathoadrenergic activities.
    Du XJ; Feng X; Gao XM; Tan TP; Kiriazis H; Dart AM
    Br J Pharmacol; 2004 May; 142(1):107-12. PubMed ID: 15066901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. I(f) blocking potency of ivabradine is preserved under elevated endotoxin levels in human atrial myocytes.
    Scheruebel S; Koyani CN; Hallström S; Lang P; Platzer D; Mächler H; Lohner K; Malle E; Zorn-Pauly K; Pelzmann B
    J Mol Cell Cardiol; 2014 Jul; 72(100):64-73. PubMed ID: 24583250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug insight: If inhibitors as specific heart-rate-reducing agents.
    Borer JS
    Nat Clin Pract Cardiovasc Med; 2004 Dec; 1(2):103-9. PubMed ID: 16265314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine.
    Doesch AO; Celik S; Ehlermann P; Frankenstein L; Zehelein J; Koch A; Katus HA; Dengler TJ
    Transplantation; 2007 Oct; 84(8):988-96. PubMed ID: 17989604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The biological effects of ivabradine in cardiovascular disease.
    Speranza L; Franceschelli S; Riccioni G
    Molecules; 2012 Apr; 17(5):4924-35. PubMed ID: 22547315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heart rate reduction via selective 'funny' channel blockers.
    Bucchi A; Barbuti A; Baruscotti M; DiFrancesco D
    Curr Opin Pharmacol; 2007 Apr; 7(2):208-13. PubMed ID: 17267284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Selection and pharmacological characterisation of Procoralan, a selective inhibitor of the pacemaker If current].
    Vilaine JP
    Therapie; 2004; 59(5):495-505. PubMed ID: 15648301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Heart failure. Heart rate control prevents clinical complications].
    Einecke D
    MMW Fortschr Med; 2010 Sep; 152(37):12-3. PubMed ID: 21197688
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of M-mode and Doppler echocardiography to investigate the cardiotoxicity of minoxidil in beagle dogs.
    Hanton G; Gautier M; Bonnet P
    Arch Toxicol; 2004 Jan; 78(1):40-8. PubMed ID: 12937890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure.
    De Ferrari GM; Mazzuero A; Agnesina L; Bertoletti A; Lettino M; Campana C; Schwartz PJ; Tavazzi L
    Eur J Heart Fail; 2008 Jun; 10(6):550-5. PubMed ID: 18486549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical results with I(f) current inhibition by ivabradine.
    Berdeaux A
    Drugs; 2007; 67 Suppl 2():25-33. PubMed ID: 17999561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J; Varela A
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.